Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
09 December 2022 | Story Leonie Bolleurs | Photo Leonie Bolleurs
Dr Thomas Sekyi-Ampah
Dr Thomas Sekyi-Ampah, who recently received his PhD in Urban and Regional Planning at the UFS December graduation ceremonies.

“I am extremely glad that I was successful in obtaining my PhD degree. Learning is a lifelong experience, and the joy of this undertaking is immense. I will encourage others to pursue this goal later in their lives if they so desire,” said Dr Thomas Eric Sekyi-Ampah, who received his PhD degree in the Department of Urban and Regional Planning at the University of the Free State (UFS) – just more than two weeks before his 74th birthday. 

He completed his master’s degree at the UFS and decided to also pursue a PhD at the same institution, focusing on the tension between traditional leaders and the municipal planning process around the Spatial Planning and Land Use Management Act 2013 (SPLUMA), the role traditional leaders play in nature conservation, and the limitations of municipal spatial governance due to inadequate resources. In his thesis, titled: Towards a sustainable and transformative spatial governance system for municipalities with traditional leaders: A case study of Alfred Nzo District Municipality, Eastern Cape, Dr Sekyi-Ampah investigates the potential for inclusive and sustainable spatial governance in this municipal district.

His supervisor since 2018, Prof Verna Nel, Professor in the Department of Urban and Regional Planning, said the process required tenacity and hard work. “I admire his persistence.”

Impacting service delivery

Dr Sekyi-Ampah describes the Alfred Nzo District as “a deeply rural area, characterised by subsistence agriculture, where longstanding traditions and customs prevail”.

“The legacy of the 1913 Land Act and subsequent apartheid policies are evident in the pervasive poverty and high dependence on social grants,” he added. 

“For me, it was appropriate to explore the nature of the existing spatial governance and development challenges of towns and the traditional authority areas within this municipal district, as well as the relationships between the municipalities and the traditional authorities,” he said.

He continued: “Very large areas of traditional lands are located in environmentally sensitive zones. Thus, planning that takes cognisance of the environment should be paramount.”

After interviewing municipal officials, traditional leaders, local businesses, and planners with knowledge about the region, he found that although the traditional leaders have antagonistic feelings towards the implementation of SPLUMA, there is sufficient goodwill for cooperation with the local governments in the district. While the necessary plans and policies are in place, the main obstacles are the constraints experienced by the municipalities – staff, finances, and an unstable political environment.

He also found that implementing the Spatial Development Framework (SDF) in the traditional areas is a challenge, since municipalities do not control land allocation. “Planners are excluded from land allocation; thus, there is no adherence to the provisions of the SDF. This impacts service delivery, disaster management, and the judicious use of the environment in the traditional areas,” he said.

Improving sustainability of the area

Dr Sekyi-Ampah believes that he can add value through his research. It can improve the sustainability of the area if these constraints are addressed, and if traditional leaders are included in the planning and land use management processes. Ultimately, this can alleviate the plight of residents.

“I recommend the Department of Urban and Regional Planning to any prospective student, because it has a team of academics and support staff that will guarantee success for prospective students who are prepared to put in the requisite effort,” said Dr Sekyi-Ampah.

He is looking forward to continuing his research and to mentor prospective students based on the experience and wealth of knowledge obtained from this research and his experience as a town and regional planner.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept